Suvretta Capital Management LLC Has $41.61 Million Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Suvretta Capital Management LLC raised its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 16.6% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 4,913,012 shares of the specialty pharmaceutical company’s stock after acquiring an additional 701,007 shares during the period. KalVista Pharmaceuticals accounts for 1.4% of Suvretta Capital Management LLC’s portfolio, making the stock its 23rd largest position. Suvretta Capital Management LLC owned about 0.10% of KalVista Pharmaceuticals worth $41,613,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Rafferty Asset Management LLC grew its holdings in KalVista Pharmaceuticals by 24.3% in the 4th quarter. Rafferty Asset Management LLC now owns 54,466 shares of the specialty pharmaceutical company’s stock valued at $461,000 after buying an additional 10,636 shares during the last quarter. ProShare Advisors LLC acquired a new stake in KalVista Pharmaceuticals in the 4th quarter valued at approximately $101,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in KalVista Pharmaceuticals by 27.4% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 172,693 shares of the specialty pharmaceutical company’s stock valued at $1,463,000 after buying an additional 37,141 shares during the last quarter. Octagon Capital Advisors LP acquired a new stake in KalVista Pharmaceuticals in the 4th quarter valued at approximately $11,604,000. Finally, Graham Capital Management L.P. acquired a new stake in KalVista Pharmaceuticals in the 4th quarter valued at approximately $89,000.

KalVista Pharmaceuticals Price Performance

Shares of KALV stock opened at $11.93 on Friday. The stock’s fifty day simple moving average is $12.02 and its 200 day simple moving average is $10.42. The firm has a market cap of $593.11 million, a price-to-earnings ratio of -3.28 and a beta of 0.05. KalVista Pharmaceuticals, Inc. has a one year low of $7.30 and a one year high of $15.50.

Insider Activity at KalVista Pharmaceuticals

In related news, CEO Benjamin L. Palleiko sold 5,104 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total value of $50,121.28. Following the sale, the chief executive officer now owns 278,855 shares of the company’s stock, valued at $2,738,356.10. The trade was a 1.80% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Venrock Healthcare Capital Par purchased 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 9th. The stock was bought at an average cost of $9.42 per share, for a total transaction of $235,500.00. Following the purchase, the insider now owns 5,303,985 shares in the company, valued at $49,963,538.70. This represents a 0.47% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 17,292 shares of company stock valued at $184,625 in the last 90 days. 10.50% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, March 14th. Jones Trading reissued a “buy” rating and set a $30.00 price objective on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. Citizens Jmp raised KalVista Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 31st. JMP Securities assumed coverage on KalVista Pharmaceuticals in a report on Friday, January 31st. They set an “outperform” rating and a $19.00 price objective on the stock. Finally, Needham & Company LLC reissued a “buy” rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a report on Tuesday, April 8th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $24.83.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).